U.S. Stock Futures Flat Ahead of July CPI Data 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Trump Weighs Capital Gains Tax Cuts Ahead of Midterms 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Australia Sets New Minimum Pay, Insurance Rules for Gig Workers 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
ADNOC Gas Targets Up to $4B Profit in 2026 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Gold Prices Rise as Fed Rate Hike Bets Ease 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Lotte Group is set to acquire a bioindustry CMO plant located in the United States. The move has been announced on Thursday, May 5, and this also signals the company’s entrance into the bio business.
Currently, the acquisition process for the contract manufacturing organization (CMO) facility is still ongoing. Investment banking industry insiders said that Lotte Group has taken this step to buy the CMO plant after it stated that the bioindustry will be its new growth engine.
According to The Korea Times, CMOs are firms that specialize in the production of biopharmaceuticals that were developed by other companies. Lotte Group’s new CMO business will be headed by Lee Won Jik, a former executive at Samsung Biologics that the company recently hired. He has been tasked to develop and grow this business unit that the Lotte Group set up.
Lee will also be leading the acquisition efforts of the CMO as per the report. It was only last month when the South Korean multinational conglomerate declared during its general shareholders' meeting that its next growth engine for the future will be the bioindustry. Lotte Holdings will be investing directly in this business and will provide support to help it grow and succeed.
Meanwhile, as part of its entrance into the CMO business, Lotte Group applied for a trademark for its new biz. The company registered “Lotte Biologics” with the Korean Intellectual Property Office (KIPO) to officially launch its bio venture.
It was added that under the new Lotte Biologics banner, Lotte will also be participating in the largest bioindustry expo in the world called the Bio International Convention (Bio USA) which is set to take place next month in San Diego, California.
KIPO revealed that Lotte Holdings applied for the patent last week and aside from the name, it also trademarked some business areas such as customized manufacturing of biopharmaceuticals and drug processing and medical diagnostic devices for virus testing, The Korea Herald reported.
“Registering the trademark of Lotte Biologics was a part of preparations for the group’s bio business,” an official of Lotte Holdings stated. “We are reviewing various ways to enter the bio industry, but nothing has been confirmed at the moment.”
